The Cellular Apoptosis Susceptibility Protein (CAS) Promotes Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis and Cell Proliferation
Overview
Authors
Affiliations
A signature event during the cell intrinsic apoptotic pathway is mitochondrial outer membrane permeabilization, leading to formation of the apoptosome, a caspase activation complex. The cellular apoptosis susceptibility protein (CAS) can facilitate apoptosome assembly by stimulating nucleotide exchange on Apaf-1 following binding of cytochrome c. We report here that CAS expression itself is up-regulated during tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, and knockdown of CAS renders cells resistant to TRAIL. We find that TRAIL induces up-regulation of CAS in a posttranscriptional, caspase-8-dependent manner through degradation of cIAP1, an E3 ligase that targets CAS for ubiquitin-dependent proteasomal degradation. We identified a novel signaling pathway whereby caspase-8 engages a feedforward cascade that leads to CAS up-regulation and amplifies the apoptotic signal. Furthermore, in silico analysis revealed that expression of CAS is up-regulated at both the mRNA and DNA levels in human breast tumors, consistent with its role in promoting cell proliferation. Overexpression of various oncogenes led to CAS up-regulation in non-transformed cells. Intriguingly, oncogene-induced CAS up-regulation also resulted in greater susceptibility to TRAIL-induced cell death, consistent with its proapoptotic function. These findings suggest that CAS plays contrasting roles in proliferation and apoptosis and that overexpression of CAS in tumors could serve as a potential biomarker to guide therapeutic choices.
Mechanism of exportin retention in the cell nucleus.
Kapinos L, Kalita J, Kassianidou E, Rencurel C, Lim R J Cell Biol. 2024; 223(2).
PMID: 38241019 PMC: 10798875. DOI: 10.1083/jcb.202306094.
Mechanisms of Resistance to Immunotoxins Containing Exotoxin A in Cancer Therapy.
Dieffenbach M, Pastan I Biomolecules. 2020; 10(7).
PMID: 32630017 PMC: 7408526. DOI: 10.3390/biom10070979.
Ye M, Han R, Shi J, Wang X, Zhao A, Li F Med Oncol. 2020; 37(5):43.
PMID: 32270348 DOI: 10.1007/s12032-020-01366-w.
Zhang G, Xu Y, Zhou H Med Sci Monit. 2019; 25:7853-7863.
PMID: 31630150 PMC: 6820344. DOI: 10.12659/MSM.916246.
Sun J, Jiang W, Tian D, Guo Q, Shen Z Onco Targets Ther. 2018; 11:8227-8237.
PMID: 30538492 PMC: 6254541. DOI: 10.2147/OTT.S179844.